An exceptional innovator, Jeff Geschwind, MD, is an interventional oncologist with extensive experience in the management of patients with liver cancer. He is considered a world expert on liver cancer. Currently, he serves as the Medical Director of Oncology, Image-Guided Therapy, and Imaging Core Lab at NAMSA, one of the premier contract research organizations in the US. Moreover, he is a Medical Advisor (Medical Affairs) for HistoSonics, which is developing a non-invasive, ultrasound-based therapy for liver cancer and other cancers. Dr. Jeff Geschwind also consults for Philips Healthcare and Cage Pharma, the latter of which he founded in 2009 to develop cancer drugs targeting tumor metabolism.
Dr. Jeff Geschwind has been the lead or co-investigator on no less than 50 clinical trials, including some that were care changing. He holds several patents for his research on a promising cancer therapy and formed a company based on these research discoveries.
Previously, Dr. Geschwind was a professor at the Johns Hopkins University School of Medicine and the Yale University School of Medicine, where he served as Chairman of the Department of Radiology and Biomedical Imaging. After he left Yale, he became the Director of Oncology at USA Clinics Group, the largest outpatient practice in the US.
Widely regarded as a pioneer in interventional oncology, Dr. Geschwind received the Wilhelm Conrad Rontgen Honorary Award from the European Society of Radiology and the Ernest Ring Academic Development Program Grant from the Society of Interventional Radiology, among many other awards and accomplishments. He earned his MD from Boston University School of Medicine.